Skip to main content
. Author manuscript; available in PMC: 2023 Sep 13.
Published in final edited form as: Biomed Pharmacother. 2023 Mar 12;161:114494. doi: 10.1016/j.biopha.2023.114494

Fig. 2.

Fig. 2.

Alamar blue cell viability assays with multiple cancer cell lines. Percent growth inhibition is shown for (A) colon (COLO205, LIM1215), (B) breast (MDA-MB-231, SKBR-3), (C) ovarian (SKOV-3, OVCAR-3) and (D) glioblastoma (U87-MG) and non-small cell lung cancer (HCC-827) tumor cell lines treated with human 1H5. The data represent mean of triplicate determinations and two independent experiments, and the bar plots show the effect of treatment of mAbs on cancer cells relative to the control, mean ± SEM (described in Materials and Methods).